Unitaid was created in 2006 to invest in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more affordably and more effectively. Since its establishment, Unitaid has received over US$ 3 billion in contributions from donors, with our main donors being France, the United Kingdom, Norway, the Bill & Melinda Gates Foundation, Brazil, Spain, the Republic of Korea, and Chile. Currently, we manage a portfolio of 48 grants worth US$ 1.29 billion in more than 40 countries.
Unitaid’s investments are highly effective at delivering innovative health solutions of high quality that ultimately benefit millions of people. Unitaid has a strong track record of kick-starting innovation and making the global response faster, more affordable and more effective. Our programmes are delivering a range of solutions, such as: next generation diagnostics allowing faster, easy-to-use and precise screening; new medicines generating less resistance; new regimens that are specially adapted to children’s needs; and new molecules allowing shorter treatment regimens. We make these innovations available in record time by accelerating their development, bringing them to market and ensuring they can be delivered at scale.
Innovations such as these are transforming the way diseases are prevented, diagnosed and treated in dozens of countries and benefit millions of people. As countries and partners scale up these innovations, hundreds of thousands of additional lives are saved, reaping huge savings for health systems worldwide. All in all, Unitaid’s investments deliver a strong punch, yielding an estimated return of US$ 7 to US$ 20 per dollar invested.
- Download the full document here.